Literature DB >> 2120394

High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma: a case report.

U M Saarinen1, H Pihko, A Mäkipernaa.   

Abstract

High-dose thiotepa with autologous bone marrow rescue is a new and promising treatment modality in several kinds of solid tumors. We used this regimen in a pediatric patient who had the third recurrence of his malignant oligodendroglioma of brain that developed during '8 in 1' chemotherapy. We achieved complete response after a total dose of 1125 mg/m2 of intravenous thiotepa. Good penetration into the CNS renders thiotepa potentially useful for chemosensitive brain tumors, and one course of high-dose thiotepa can be administered with acceptable toxicity by utilizing autologous bone marrow rescue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120394     DOI: 10.1007/bf00167069

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  12 in total

1.  Summary of results with triethylene thiophosphoramide.

Authors:  J C WRIGHT; F M GOLOMB; S L GUMPORT
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

2.  Intrathecal N, N', N"-triethylenethiophosphoramide [thio-TEPA (NSC 6396)] in the treatment of malignant meningeal disease: phase I-II study.

Authors:  P H Gutin; H D Weiss; P H Wiernik; M D Walker
Journal:  Cancer       Date:  1976-10       Impact factor: 6.860

3.  Megadose chemotherapy with bone marrow rescue.

Authors:  H J Fingert; F H Hochberg
Journal:  Prog Exp Tumor Res       Date:  1984

4.  Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate.

Authors:  D L Trump; S A Grossman; G Thompson; K Murray; M Wharam
Journal:  Cancer Treat Rep       Date:  1982-07

5.  High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.

Authors:  H M Lazarus; M D Reed; T R Spitzer; M S Rabaa; J L Blumer
Journal:  Cancer Treat Rep       Date:  1987 Jul-Aug

6.  Eight drugs in one day chemotherapy for brain tumors: experience in 107 children and rationale for preradiation chemotherapy.

Authors:  T W Pendergrass; J M Milstein; J R Geyer; A F Mulne; E J Kosnik; J D Morris; R L Heideman; F B Ruymann; J T Stuntz; W A Bleyer
Journal:  J Clin Oncol       Date:  1987-08       Impact factor: 44.544

7.  Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.

Authors:  G L Phillips; S N Wolff; J W Fay; R H Herzig; H M Lazarus; C Schold; G P Herzig
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

Review 8.  High dose chemotherapy with autologous bone marrow rescue for high grade gliomas of the brain: a potential for improvement in therapeutic results.

Authors:  A Kessinger
Journal:  Neurosurgery       Date:  1984-11       Impact factor: 4.654

9.  High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children.

Authors:  J C Allen; L Helson
Journal:  J Neurosurg       Date:  1981-11       Impact factor: 5.115

10.  Triethylenethiophosphoramide (thio-tepa) in the treatment of neoplastic disease.

Authors:  J E ULTMANN; G A HYMAN; C CRANDALL; H NAUJOKS; A GELLHORN
Journal:  Cancer       Date:  1957 Sep-Oct       Impact factor: 6.860

View more
  2 in total

1.  Treatment of recurrent malignant supratentorial gliomas with the association of procarbazine, thiotepa and vincristine: a phase II study.

Authors:  A Ameri; M Poisson; Q M Chen; J Y Delattre
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

2.  High-dose thiotepa-related neurotoxicity and the role of tramadol in children.

Authors:  Christophe Maritaz; Francois Lemare; Agnes Laplanche; Sylvie Demirdjian; Dominique Valteau-Couanet; Christelle Dufour
Journal:  BMC Cancer       Date:  2018-02-13       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.